Arcus Biosciences (RCUS) Other Working Capital Changes (2017 - 2022)

Arcus Biosciences' Other Working Capital Changes history runs 9 years deep, the most recent figure standing at -$16.0 million for Q1 2026.

• On a quarterly basis, Other Working Capital Changes rose 42.86% year-over-year to -$16.0 million in Q1 2026; TTM through Mar 2026 was $20.0 million, a 48.72% decrease from a year earlier, with the FY2025 full-year figure at $8.0 million, down 68.0% from the prior year.
• Other Working Capital Changes retreated to -$16.0 million in Q1 2026 per RCUS's latest filing, from $222.0 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $6.3 million in Q3 2021 and bottomed at -$6.6 million in Q4 2021.
• The 5-year median for Other Working Capital Changes is $193000.0 (2019), against an average of -$106842.1.
• Across the five-year window, Other Working Capital Changes tumbled 2400.0% in 2023 and soared 880.0% in 2024, its largest moves.
• Year by year, Other Working Capital Changes stood at $11.0 million in 2022, then tumbled by 145.45% to -$5.0 million in 2023, then surged by 880.0% to $39.0 million in 2024, then surged by 469.23% to $222.0 million in 2025, then sank by 107.21% to -$16.0 million in 2026.
• Per Business Quant, the three latest RCUS Other Working Capital Changes figures stand at -$16.0 million (Q1 2026), $222.0 million (Q4 2025), and -$214.0 million (Q3 2025).